Bio
Founded MVM in 1997. Prior to setting up MVM, was responsible for early stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. Has published more than 50 papers on the molecular genetics of human disease. Has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. Practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas' Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. Member of the boards of Biomedix Inc, BioVex Group Inc, Cara Therapeutics Inc and Cortria Corporation. He was previously a director of Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals Inc, New Chemical Entities Inc, Nova Science Ltd, Sangamo Biosciences Inc, Spherics Inc, UpToDate Inc, and Xention Ltd. Degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.
Career
|
MVM Life Science Partners LLPVenture capital firm which invests in technologies and products for the life science and healthcare marketsEmail: [email protected] |